在PCI后接受克洛皮多格雷尔治疗的患者中,ABCB1基因多态与高血糖和MACE之间的关联
Bo Zhou1, Chuanshen Shi2, Qike Xu1
1Clinical Pharmacy, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, People's Republic of China.
在PCI后接受克洛皮多格勒治疗的患者中,ABCB1 C3435T基因变异是主要心血管不良事件 (MACE) 的风险因素. 然而,具有正常血糖的ABCB1CC基因型可能会在年轻患者中提供保护.
科学领域:
- 心血管医学
- 药物基因组学
- 遗传学
背景情况:
- 克洛皮多格勒是经皮冠状动脉干预 (PCI) 后广泛使用的抗血小板药物.
- 基因变异,如ABCB1基因,可以影响药物反应和临床结果.
- 过高血糖是已知的心血管事件的危险因素.
研究的目的:
- 研究ABCB1 C3435T基因多态性,高血糖和主要心血管不良事件 (MACE) 风险之间的关联.
- 评估这些因素对在PCI后接受克洛皮多格勒治疗的患者的影响.
主要方法:
- 在PCI后对117名用克洛皮多格雷尔治疗的患者进行了研究.
- 使用现场光杂交确定了ABCB1 C3435T基因型.
- 根据基线特征,空腹血糖和临床结果,物流回归分析确定了MACE的独立风险因素.
主要成果:
- 鉴定出ABCB1 C3435T基因型是MACE的一个独立风险因素 (P=0. 024,OR=5. 584).
- 其他独立的MACE风险因素包括年龄,有过高血压和有过糖尿病.
- 在75岁以下的患者中,ABCB1 CC基因型与正常血糖结合显示出对MACE的保护作用 (P=0. 023,OR=0. 147).
结论:
- 在PCI后接受克洛皮多格勒治疗的患者中,ABCB1 C3435T基因型是MACE的重要独立风险因素.
- 在75岁以下的患者中,ABCB1 CC基因型和血糖正常的组合可能会对MACE产生保护作用.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
相关概念视频
Coronary Artery Disease I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Coronary Artery Disease V: Interprofessional Care
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
